530 related articles for article (PubMed ID: 33550034)
1. Clinically relevant cell culture models and their significance in isolation, pathogenesis, vaccine development, repurposing and screening of new drugs for SARS-CoV-2: a systematic review.
Kumar S; Sarma P; Kaur H; Prajapat M; Bhattacharyya A; Avti P; Sehkhar N; Kaur H; Bansal S; Mahendiratta S; Mahalmani VM; Singh H; Prakash A; Kuhad A; Medhi B
Tissue Cell; 2021 Jun; 70():101497. PubMed ID: 33550034
[TBL] [Abstract][Full Text] [Related]
2. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF
Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527
[TBL] [Abstract][Full Text] [Related]
3. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells.
Grau-Expósito J; Perea D; Suppi M; Massana N; Vergara A; Soler MJ; Trinite B; Blanco J; García-Pérez J; Alcamí J; Serrano-Mollar A; Rosado J; Falcó V; Genescà M; Buzon MJ
PLoS Pathog; 2022 Jan; 18(1):e1010171. PubMed ID: 35025963
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
[TBL] [Abstract][Full Text] [Related]
6. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
[TBL] [Abstract][Full Text] [Related]
7. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
Terrier O; Dilly S; Pizzorno A; Chalupska D; Humpolickova J; Bouřa E; Berenbaum F; Quideau S; Lina B; Fève B; Adnet F; Sabbah M; Rosa-Calatrava M; Maréchal V; Henri J; Slama-Schwok A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946802
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of itraconazole against SARS-CoV-2.
Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
[TBL] [Abstract][Full Text] [Related]
10. Review on
Cetin Y; Aydinlik S; Gungor A; Kan T; Avsar T; Durdagi S
Curr Med Chem; 2022; 29(38):5925-5948. PubMed ID: 35761502
[TBL] [Abstract][Full Text] [Related]
11. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
Salgado-Benvindo C; Thaler M; Tas A; Ogando NS; Bredenbeek PJ; Ninaber DK; Wang Y; Hiemstra PS; Snijder EJ; van Hemert MJ
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513797
[TBL] [Abstract][Full Text] [Related]
12. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
13. Kite-Shaped Molecules Block SARS-CoV-2 Cell Entry at a Post-Attachment Step.
Chan SW; Shafi T; Ford RC
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835112
[TBL] [Abstract][Full Text] [Related]
14. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
[TBL] [Abstract][Full Text] [Related]
15. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
16. Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort.
Zaliani A; Vangeel L; Reinshagen J; Iaconis D; Kuzikov M; Keminer O; Wolf M; Ellinger B; Esposito F; Corona A; Tramontano E; Manelfi C; Herzog K; Jochmans D; De Jonghe S; Chiu W; Francken T; Schepers J; Collard C; Abbasi K; Claussen C; Summa V; Beccari AR; Neyts J; Gribbon P; Leyssen P
Sci Data; 2022 Jul; 9(1):405. PubMed ID: 35831315
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19.
Le BL; Andreoletti G; Oskotsky T; Vallejo-Gracia A; Rosales R; Yu K; Kosti I; Leon KE; Bunis DG; Li C; Kumar GR; White KM; García-Sastre A; Ott M; Sirota M
Sci Rep; 2021 Jun; 11(1):12310. PubMed ID: 34112877
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2-host proteome interactions for antiviral drug discovery.
Liu X; Huuskonen S; Laitinen T; Redchuk T; Bogacheva M; Salokas K; Pöhner I; Öhman T; Tonduru AK; Hassinen A; Gawriyski L; Keskitalo S; Vartiainen MK; Pietiäinen V; Poso A; Varjosalo M
Mol Syst Biol; 2021 Nov; 17(11):e10396. PubMed ID: 34709727
[TBL] [Abstract][Full Text] [Related]
20. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19.
van de Leemput J; Han Z
Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
